Inmed Pharmaceuticals INC 8-K filings

InMed Pharmaceuticals held its annual general meeting on December 18, 2024, where shareholders voted on the election of directors and the appointment of auditors.

InMed Pharmaceuticals has entered into a standby equity purchase agreement with YA II PN, LTD, providing the company with access to up to $10 million in funding.

InMed Pharmaceuticals has announced the publication of a peer-reviewed study demonstrating the anti-inflammatory properties of cannabinol (CBN) and its potential for treating skin diseases.

InMed Pharmaceuticals announced its first quarter fiscal 2025 financial results, highlighting progress in its pharmaceutical programs and commercial operations, including a 40% revenue increase in its BayMedica business.

InMed Pharmaceuticals will consolidate its shares on a 1-for-20 basis to meet Nasdaq's minimum bid price requirement.

InMed Pharmaceuticals has received an extension from Nasdaq to implement a share consolidation by December 2, 2024, to meet the minimum bid price requirement.

InMed Pharmaceuticals has filed an international patent application for its drug candidate INM-901, targeting neurodegenerative diseases including Alzheimer's.

InMed Pharmaceuticals will participate in a Fierce Biotech webinar on November 12th, 2024, to discuss neuroinflammation in Alzheimer's disease.

InMed Pharmaceuticals has appointed Dr. Barry Greenberg, a leading expert in Alzheimer's disease research, to its Scientific Advisory Board.

InMed Pharmaceuticals reported a revenue increase of 11% for fiscal year 2024, alongside advancements in their Alzheimer's and AMD drug programs.

InMed Pharmaceuticals has set the date for its Annual General Meeting and established the record date for voting.

InMed Pharmaceuticals has appealed a Nasdaq delisting notice and secured a hearing to present its plan to regain compliance with the minimum bid price rule.

InMed Pharmaceuticals has secured three new U.S. patents, enhancing its intellectual property portfolio in key areas such as epidermolysis bullosa treatment, biosynthesis manufacturing, and ocular drug delivery.

InMed Pharmaceuticals has confirmed that its drug candidate INM-901 can be administered orally, achieving similar brain drug concentrations as an injection, which is a significant step in its development for Alzheimer's disease.

InMed Pharmaceuticals reports favorable behavioral outcomes in a long-term preclinical study of INM-901 for Alzheimer's disease, confirming earlier positive results.

InMed Pharmaceuticals has amended its At-the-Market Offering Agreement to update sales settlement provisions, reimbursement terms, and company representations.

InMed Pharmaceuticals will present a corporate overview at the Emerging Growth Conference on June 13, 2024.

InMed Pharmaceuticals announced positive preclinical data in its Alzheimer's and dry AMD programs, along with its fiscal third quarter 2024 financial results, closing the quarter with $7.9 million in cash.

InMed Pharmaceuticals has appointed Dr. David G. Morgan, a leading expert in neurodegenerative diseases, to its Scientific Advisory Board to advance its INM-901 program for Alzheimer's treatment.

InMed Pharmaceuticals has released additional preclinical data showing positive effects of INM-089 in treating dry Age-Related Macular Degeneration (AMD).

InMed Pharmaceuticals announces positive preclinical data for INM-901, demonstrating favorable pharmacological and behavioral effects in Alzheimer's disease models.

InMed Pharmaceuticals has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement for continued listing.

InMed Pharmaceuticals announced a 164% revenue increase in its BayMedica subsidiary and progress in its Alzheimer's and Age-Related Macular Degeneration preclinical programs for the second quarter of fiscal year 2024.

InMed Pharmaceuticals has appointed Netta Jagpal as its new Chief Financial Officer and Corporate Secretary, effective February 20, 2024, bringing extensive biotech financial leadership experience to the company.

InMed Pharmaceuticals will discuss its pharmaceutical pipeline and 2024 strategic priorities in a fireside chat with Water Tower Research on January 25, 2024.

InMed Pharmaceuticals is advancing its drug development programs for Alzheimer's and age-related macular degeneration while its BayMedica subsidiary continues to grow revenue.